中文网站正在持续更新中,请密切关注我们康肽生物的最新动态,或点击访问右上角的英文官方网站 www.phoenixpeptide.com
PHOENIX PHARMACEUTICALS, INC. TOP HOME PAGE
Top Catalog English Version | My Account | 联系我们 | China



 多肽



 标记多肽 



 多肽激素文库



 抗体 



 免疫试剂盒 



 生物标志物阵列 



 多肽样品检测



 自定义肽链合成及GMP



 产品目录索取



 样品准备



 提问和解答


Corticotropin Releasing Factor (CRF)

The corticotropin-releasing hormone system in the regulation of energy balance in obesity

The corticotropin-releasing hormone system in the regulation of energy balance in obesity

The view that energy balance is regulated has gained acceptance in recent years. An important role in this regulation is played by brain circuitries involved in the control of energy intake (food intake) and energy expenditure (thermogenesis) that are capable of integrating peripheral signals, produced by perturbations of adipose tissue mass, into messages to effectors of food intake and energy expenditure, so as to prevent substantial variations in the level of energy reserves. More than one neurosystem has been reported to genuinely participate in the regulation of energy balance. Among them is the corticotropin-releasing hormone (CRH) system. This system, with its numerous clusters of brain neurons, its closely related peptide urocortin, its two receptor types and its binding protein, all generally widely distributed throughout the brain, forms a network of neuronal pathways capable of interacting with the circuitries controlling food intake and energy expenditure. In addition, CRH and urocortin's anorectic and thermogenic actions appear to be coordinated to optimize energy losses. Finally, the CRH system seems to demonstrate a certain degree of plasticity in obesity and in response to food deprivation that is consistent with its action on food intake and thermogenesis. The observations have been made that food deprivation and obesity can blunt the expression of the CRH type 2alpha receptor in the ventromedial hypothalamic nucleus and can induce the expression of the CRH-binding protein (a CRH-inactivating protein) in brain areas involved in the anorectic and thermogenic actions of CRH.

Richard D, Huang Q, Timofeeva E. The corticotropin-releasing hormone system in the regulation of energy balance in obesity. Int J Obes Relat Metab Disord 2000 Jun;24 Suppl 2:S36-9


The corticotropin-releasing factor family of peptides and CRF receptors: their roles in the regulation of energy balance

The corticotropin-releasing factor (CRF) system could play a significant role in the regulation of energy balance. This system, which includes CRF, CRF-related peptides and CRF receptors, is part of a huge network of cells connected to central and peripheral pathways modulating energy metabolism. CRF and CRF-related peptides, which elicit their effects through G-protein-coupled receptors known in mammals as CRF(1) receptor and CRF(2) receptor, are capable of strong anorectic and thermogenic effects. Also supporting a role for the CRF system in the regulation of energy balance are findings demonstrating alterations in this system in obese and food-deprived animals that concur to facilitate energy deposition. In recent years, great progress has been made in understanding the specific physiological roles of the CRF system. In that respect, the discovery of urocortins II and III, two endogenous ligands of the CRF(2) receptor, and the development of selective and long-acting antagonists for the CRF receptors, have led to a better comprehension of the role of the CRF system in the regulation of energy balance. Although there are still important unresolved issues in the field of CRF research, the progress made recently warrants investigations aimed at evaluating the CRF system as a potential target for anti-obesity drugs.

Richard D, Lin Q, Timofeeva E. The corticotropin-releasing factor family of peptides and CRF receptors: their roles in the regulation of energy balance. Eur J Pharmacol 2002 Apr 12;440(2-3):189-97


Suppression of food intake induced by corticotropin-releasing factor family in neonatal chicks

Corticotropin-releasing factor (CRF), urocortin and urotensin I share amino acid sequences, and they inhibit food intake in mammals. CRF plays a potent role in decreasing food intake in avian species, but the effects of urocortin and urotensin I have not been investigated. Therefore, the effect of these three peptides on food intake in the neonatal chick was compared. In Experiment 1, birds were injected intracerebroventricularly (i.c.v.) with either 0, 0.01, 0.1 or 1 microg of urocortin following a 3-h fast, and food intake was measured for 2 h post-injection. Food intake was suppressed in a dose-dependent manner. Using a similar design in Experiment 2, the effect of urotensin I was investigated. Urotensin I appeared to suppress food intake in neonatal chicks more than urocortin did. In Experiment 3, the efficacy of CRF, urocortin and urotensin I was directly compared using one dose, 0.1 microg. The results indicated that the suppressive effect on food intake was strongest for CRF followed by urotensin I, then urocortin. These results suggest that the structure of receptors for the CRF family in chicks may be somewhat different than in mammals.

Zhang R, Nakanishi T, Ohgushi A, Ando R, Yoshimatsu T, Denbow DM, Furuse M.   Suppression of food intake induced by corticotropin-releasing factor family in neonatal chicks.  Eur J Pharmacol 2001 Sep 7;427(1):37-41


CRF-Receptor 2 / CRH-R2

A G-Protein-Coupled Receptor

CRFR2

Schematic representation of amino acids within the CRH/CRH-related agonists sequence important for determining CRH-R subtype selectivity. It is now accepted that amino acid residues 32–41 are important for receptor binding, whereas residues 1–16 are responsible for both binding and receptor activation. Residues present in the domain 17–31 appear to function as a linker providing the appropriate spatial and conformational support for the two binding regions. CRH-R2 selective agonists contain a proline at position 11 and alanine residues at positions 35 and 39 (the numbering of residues is based on h/rCRH sequence). In contrast, CRH-R nonselective peptides contain an arginine at position 35 and an acidic amino acid at position 39.

Edward W. Hillhouse and Dimitris K. Grammatopoulos . Endocrine Reviews 27 (3): 260-286

Rat brain tissue stained with CRF (H,R) Antibody

Rat Brain

tl


Suggested starting dilution for immunohistological staining:

tl
 
arrow
Tissue Sample Rat hypothalamus
dot
Fixative 10% Formalin
dot
Embedding Paraffin
dot
Negative control No primary antibody
dot
Pretreatment Target Retrieval 25 min (Steam)
dot
Blocking 2% Normal Goat Serum
dot
Primary Antibody Anti-Corticotropin Releasing Factor (CRF) (Human, Rat) Serum
dot
Optimal Dilution 1: 100
dot
Secondary Antibody Goat anti-Rabbit IgG, Biotinylated (1:400)
dot
Amplification ABC (Vector)
dot
Detection system HRP
dot
substrate DAB (Sigma)
dot
Counterstained Hematoxylin
 
 

 

 
Specificity / Crossreactivity

 
 
arrow
Peptide
% Crossreactivity
1
CRF (Human, Rat)
100
0
ACTH (Human)
0
9
LH-RH
0
8
PACAP-38 (Human, Rat, Ovine)
0
7
[Arg8]-Vasopressin
0
6
Urocortin (Human)
0
5
Urocortin (Rat)
0
4
BNP-45 (Rat)
0
 
2
3

Western Blot Analysis of CRF R2 (H-006-24)

westernBlot

CRF (Human, Mouse, Rat)

EIA Kits (EK-019-06)

Extraction free EIA Kits (EKE-019-06)

Linear Range: 0.33-3.73 ng/ml

0.22-5.5ng/ml

 

Fluroscent EIA Kits (FEK-019-06)

Chemiluminescent EIA Kits (CEK-019-06)

Linear Range: 45-868 pg/ml
7 times more sensitive than normal EIA kits
Linear Range: 30.4 - 709 pg/ml
10 times more sensitive than normal EIA kits

 

sequence

%crf%


分类搜索
关键字搜索
按字母搜索
A B C D E F G H I J K L M N
O P Q R S T U V W X Y Z

Copyright 2019 PHOENIX BIOTECH